Overview

Nal-IRI With 5-fluorouracil (5-FU) and Leucovorin or Gemcitabine Plus Cisplatin in Advanced Biliary-tract Cancer

Status:
Active, not recruiting

Trial end date:
2022-07-01

Target enrollment:

Participant gender:

Summary

AIO-YMO/HEP-0315 (NIFE) is an open label, non-comparative, randomized, multicenter phase II trial

Phase:

Phase 2

Details

Lead Sponsor:

AIO-Studien-gGmbH

Collaborators:

Baxalta GmbH
Institut für Klinisch-Onkologische Forschung (IKF) am Krankenhaus Nordwest GmbH
Institut für Klinisch-Onkologische Forschung der Krankenhaus Nordwest GmbH
Servier
Shire

Treatments:

Cisplatin
Fluorouracil
Gemcitabine
Leucovorin